Bristol Myers Squibb Receives European Commission Approval of CAMZYOS® (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
PRINCETON, N.J.--(BUSINESS WIRE)--Jun 26, 2023--
Source: joplinglobe.com
Page 49 - Risk Evaluation News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Risk Evaluation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Risk Evaluation Today - Breaking & Trending Today
Bristol Myers Squibb Receives European Commission Approval of CAMZYOS® (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
CAMZYOS is the first and only cardiac myosin inhibitor approved in the European Union Approval based on two positive Phase 3 trials, EXPLORER-HCM and VALOR-HCM, demonstrating significant benefit in patients treated with CAMZYOS versus placebo
Source: marketscreener.com
Why Avadel Pharmaceuticals (AVDL) Stock Is Trading Lower Premarket Today - Avadel Pharmaceuticals (NASDAQ:AVDL), Jazz Pharmaceuticals (NASDAQ:JAZZ)
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has filed suit against the FDA for approving Avadel Pharmaceuticals Plc's (NASDAQ: AVDL) Lumryz (sodium oxybate extended-release) for cataplexy or excessive day
Source: benzinga.com
Jazz Pharmaceuticals Sues FDA Over Approval Of Rival Product, Calls It 'Unlawful'
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has filed suit against the FDA for approving Avadel Pharmaceuticals Plc's (NASDAQ: AVDL) Lumryz (sodium oxybate extended-release) for cataplexy or excessive daytime sleepiness in adult patients with narcolepsy. Jazz says Avadel's Lumryz is an extended-release reformulation of its high sodium oxybate product Xyrem for narcolepsy. Jazz argues that the approval was unlawful and violates the orphan drug exclusivity of Xywav. In an SEC filing, Jazz alleges that
Source: yahoo.com
Self-Medicating: More Than Half of At-Home Ketamine Users Misuse the Treatment
1 in 5 respondents reported using psychedelic drugs for the purpose of self-treating anxiety, depression, or other mental illnesses.
Source: psychiatrictimes.com